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Synaptosomal-associated protein of 25 kDa (SNAP-25) is a protein
that participates in the regulation of synaptic vesicle exocytosis
through the formation of the soluble NSF attachment protein recep-
tor complex and modulates voltage-gated calcium channels activity.
The Snap25 gene has been associated with schizophrenia, attention
deﬁcit hyperactivity disorder, and bipolar disorder, and lower levels
of SNAP-25 have been described in patients with schizophrenia.
We used SNAP-25 heterozygous (SNAP-25+/−) mice to investigate
at which extent the reduction of the protein levels affects neuronal
network function and mouse behavior. As interactions of genotype
with the speciﬁc laboratory conditions may impact behavioral
results, the study was performed through a multilaboratory study in
which behavioral tests were replicated in at least 2 of 3 distinct
European laboratories. Reductions of SNAP-25 levels were associ-
ated with a moderate hyperactivity, which disappeared in the adult
animals, and with impaired associative learning and memory.
Electroencephalographic recordings revealed the occurrence of
frequent spikes, suggesting a diffuse network hyperexcitability.
Consistently, SNAP-25+/− mice displayed higher susceptibility to
kainate-induced seizures, paralleled by degeneration of hilar
neurons. Notably, both EEG proﬁle and cognitive defects were im-
proved by antiepileptic drugs. These results indicate that reduction
of SNAP-25 expression is associated to generation of epileptiform
discharges and cognitive dysfunctions, which can be effectively
treated by antiepileptic drugs.
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Introduction
Synapses are fundamental brain structures that mediate
information transfer between neurons. Synaptic dysfunctions
contribute to a large number of psychiatric diseases, including
schizophrenia, autism, and intellectual disability, which are
therefore called “synaptopathies” (Grant 2012). Synaptosomal-
associated protein of 25 kDa (SNAP-25) is a soluble NSF at-
tachment protein receptor protein, tethered to the plasma
membrane via several cysteine-linked palmytoil chains, that
participates in synaptic vesicle exocytosis through the for-
mation of a complex with syntaxin and with the synaptic
vesicle protein synaptobrevin/VAMP (Jahn and Scheller 2006;
Südhof and Rothman 2009). SNAP-25 also interacts with and
modulates the activity of various voltage-gated ion channels
(VGCC) (Atlas 2001; Zamponi 2003; Catterall and Few 2008;
Condliffe et al. 2010).
SNAP-25 is involved in different psychiatric disorders.
Case–control- or family-based studies indicated that the
Snap25 gene is associated with attention deﬁcit hyperactivity
disorder (ADHD) (Barr et al. 2000; Kustanovich et al. 2003;
Mill et al. 2004; Faraone et al. 2005; Feng et al. 2005). Accord-
ingly, Snap25 intronic single nucleotide polymorphisms
(SNPs) have been linked to inattentive hyperactivity in a
group of ADHD children (Zhang et al. 2010), and associated
with hyperactivity in autism spectrum disorders (Guerini
et al. 2011). Genome-wide linkage scan analysis for schizo-
phrenia susceptibility genes suggested the chromosomal
region 20p12.3-11, containing Snap25, as a candidate region
for the disease (Lewis et al. 2003). Also, SNAP-25 levels are
lower in the hippocampus (Young et al. 1998; Thompson
et al. 2003) and in the frontal lobe (Thompson et al. 1998) of
patients with schizophrenia. Finally, modiﬁcations of
SNAP-25 levels occur in the brain of bipolar patients (Fatemi
et al. 2001; Scarr et al. 2006), while one SNP variant in the
promoter region, associated with higher SNAP-25 expression
in prefrontal cortex, was linked with early onset of bipolar
disorder (Etain et al. 2010).
The demonstration that SNAP-25 levels are altered in psy-
chiatric diseases suggests that variations in the protein
expression may have a pathogenic effect, possibly affecting
synaptic function and network activity, and resulting in phe-
notype alterations. Indeed, homozygous mutant mice in
which Ser187 of SNAP-25 is substituted with Ala display an
altered emotional behavior (Kataoka et al. 2011), while repla-
cement of the mature SNAP-25 b isoform with the SNAP-25 a
isoform, which is present in early development, results in de-
velopmental defects, spontaneous seizures, and impaired
short-term synaptic plasticity (Johansson et al. 2008).
So far, the only evidence that reduction of SNAP-25
expression may directly impact the behavioral phenotype
derives from the analysis of the coloboma mouse, which is
characterized by a hemizygous 2-centimorgan deletion of a
segment on chromosome 2q, including the gene region en-
coding SNAP-25 (Hess et al. 1995). The coloboma mice,
largely used as a model for ADHD (Wilson 2000; reviewed in
Faraone et al. 2005; Russell 2007), display a hyperactive phe-
notype, which is reduced by the expression of the SNAP-25
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transgene (Hess et al. 1996). However, coloboma mice may
not be suited for investigating the neurophysiological and be-
havioral phenotype induced by reduction of SNAP-25 levels,
because the 37 genes that are present in the deleted region on
chromosome 2, including genes for phospholipase C beta-1
(Plcb1), coloboma (cm), Plcb4, and Jag1, may contribute to
the mice phenotype (Gunn et al. 2011).
While SNAP-25 homozygous mutant mice die at birth from
respiratory failure, heterozygous (SNAP-25+/−) mice are viable
(Washbourne et al. 2001). We used therefore SNAP-25+/−
mice to investigate at which extent selective reduction of the
protein levels, as occurring in psychiatric diseases, affects
neuronal network function and mouse behavior. The large
majority of behavioral tests were carried out in at least 2 of 3
European laboratories and generated reproducible results. We
found that SNAP-25+/− mice display hyperactivity and show
an abnormal EEG proﬁle associated with cognitive defects,
both normalized by treatment with valproate (VLP).
Materials and Methods
Animals
Male SNAP-25+/+ and SNAP-25+/− C57BL/6 mice, originally from M.C.
Wilson (University of New Mexico Health Sciences Center, Albuquer-
que, NM, USA), were provided by J. Sorensen (MPI, Goettingen).
Mice were maintained and repeatedly backcrossed on C57BL/6 back-
ground for more than 10 generations.
Zero- to six-month-old age-matched littermate mice were used. All
the experimental procedures followed the guidelines established by
the Italian Council on Animal Care and were approved by the Italian
Government decree No. 27/2010. All efforts were made to minimize
the number of subjects used and their suffering. Mice were individu-
ally housed throughout the testing period with free access to food
and water at controlled temperature (20–22 °C) with a 12-h light/dark
cycle (lights on at 7:00 AM). Genotyping was performed by PCR as
described (Washbourne et al. 2001).
Westen Blot Analysis
Homogenates from cortices of E18, P7, P14, P30, and adult (3 months
old) mice were analyzed by western blotting using anti-SNAP-25,
1:1000 (Chemicon, Temecula, CA., USA), anti-Calbindin (CB), 1:500
(Swant, Bellinzona, Switzerland), anti-beta-III-Tubulin 1:4000 (Promega
Corporation, Madison, USA), anti-alpha-Tubulin 1:2000 (Sigma-Aldrich,
St. Louis, MO), anti-vGlut1 1:2000 (Synaptic System, Gottingen,
Germany). Antibodies against SNAP-47, SNAP-29, and SNAP-23 were a
gift of R. Jahn (MPI, Gottingen). Immunoreactive bands were detected
using the Pierce ECLWestern Blotting Substrate (Thermo Fisher Scienti-
ﬁc Inc., Rockford, IL), scanned with a Bio-rad GS-800™ calibrated den-
sitometer, and analyzed with Image J software. Beta-III tubulin or
alpha-tubulin was used as loading controls. For each developmental
stage, SNAP-25/beta-III tubulin or SNAP-25/alpha tubulin optical den-
sities were normalized to the average of controls.
Immunohistochemical Analysis
Immunohistochemistry was performed on 5 SNAP-25+/+ and 3
SNAP-25+/− mice at postnatal day (P) 2 and on 3 SNAP-25+/+ and 3
SNAP-25+/− adult (P90) mice. The immunoperoxidase and immuno-
ﬂuorescence procedure was performed on free-ﬂoating sections
(Moroni et al. 2008) using the following primary antibodies: anti-CB,
1:5000, anti-nonphosphorylated neuroﬁlaments, 1:1000 (SMI311;
Sternberger Monoclonals Incorporated, Lutherville, USA),
anti-calretinin (CR), 1:3000, anti-neuropeptide Y (NPY; Peninsula
Bachem, Bubendorf, Switzerland), anti-doublecortin, 1:800 (DCX;
Cell Signaling Technology, Danvers, MA, USA), anti-cholecystokinin,
1:100 (CCK-8; Neomarkers, Fremont, CA, USA), anti-vGlut1, 1:1500
(Synaptic System, Gottingen), anti-vGlut2, 1:1000 (Synaptic System,
Gottingen), and anti-vGat, 1:1000 (Synaptic System, Gottingen). For
cytoarchitectonic analysis, selected sections were stained with thionin
(0.1% in distilled water).
qRT-PCR Analysis
Brain tissues from P7, P14, P30, and adult mice were used for real-
time PCR analysis. Sample was homogenized prior to RNA extraction
in 800 μL of Trizol. Total RNA was isolated using the NucleoSpin
miRNA (Macherey-Nagel GmbH &Co., Düren, Germany) isolation kit
according to the manufacturer’s protocol. The RNA was eluted with
30-μL Rnase-free water. All RNA was quantiﬁed by spectrophotometer
and optical density 260/280 nm ratios were determined. Reverse
transcription was performed on 2-μg RNA using Superscript III First-
Strand Synthesis System and random hexamer primers (Life Technol-
ogies, Carlsbad CA, USA). Real-time polymerase chain reaction
(qRT-PCR) was performed using 7900 HT fast-real-time PCR system
instrument (Life Technologies, Carlsbad CA, USA). The ampliﬁcation
was carried out in a total reaction volume of 11 μL, using the TaqMan
Gene Expression Master Mix (Life Technologies, Carlsbad CA, USA).
Predeveloped TaqMan Assay Reagent (FAM-MGB) for SNAP25 and
for GAPDH were purchased from PE Applied Biosystems. Each gene
was analyzed in triplicate. Data analysis was performed with the ΔΔCt
method. All RNA levels were normalized to Gapdh.
Spontaneous Motor Activity and Amphetamine Response
Spontaneous motor activity was carried out as described in Sup-
plementary Materials and Methods. Before the start of the test,
SNAP-25+/+ and SNAP-25+/− mice (7–9 weeks of age) were habituated
to the testing room for at least 1 h. Cumulative horizontal and vertical
movement counts were recorded for 4 h before and 3 h after treat-
ment., animals were treated subcutaneous (s.c.) with saline or
amphetamine sulfate (4 mg/kg) dissolved in 0.9% NaCl. Activity
measures began immediately after injection and lasted 3 h, according
to Hess et al. (1996).
Electroencephalogram
After surgery (for details see Supplementary Materials and Methods),
Electroencephalogram (EEG) activity was recorded, in a Faraday
chamber, using a Power-Lab digital acquisition system (AD Instru-
ments, Bella Vista, Australia; sampling rate 100 Hz) in freely moving
SNAP-25+/+ and SNAP-25+/− mice (n = 10 mice per genotype). EEG
traces were analyzed as described (Manfredi et al. 2009) for spike
activity. Basal cerebral activity was recorded continuously for 24 h in
freely moving mice. For each 24-h EEG recording, the mean number
of spikes was evaluated in both genotypes. After the recordings, the
EEG and video (through a video camera put inside the Faraday chamber)
were analyzed for the incidence/duration of spontaneous cortical spike
activity and the percentage of animals displaying spike activity, as pre-
viously described (Zhang et al. 2004; Manfredi et al. 2009).
Kainate-Induced Seizures
SNAP-25+/+ and SNAP-25+/− mice (n = 10 mice per genotype) received
intraperitoneal (i.p.) kainic acid (KA, Sigma Aldrich, St. Louis, MO) dis-
solved in saline at 35-mg/kg body weight. Saline-injected animals of
both genotypes were used as controls. Seizure severity was determined
as described (Bozzi et al. 2000). The rating scale value was scored
every 20 min for a maximum of 3 h, and data were used to calculate
the time-course of seizure severity for each genotype (Schauwecker
and Steward 1997; Tripathi et al. 2008). At the end of behavioral obser-
vation (3 h after KA), animals were returned to their home cages;
animals were killed at 14 days after KA for histopathological analyses.
Quantiﬁcation of NPY Staining
The quantiﬁcation method was adapted from that described in Anto-
nucci et al., 2008. Four-eight NPY-stained sections through the dorsal
hippocampus were analyzed in each KA-treated mouse (wild type
[wt], n = 5; heterozygous [het], n = 5). Images of CA3 stratum radiatum
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and of the overlying corpus callosum in each hemisphere were digi-
tized (Zeiss Axiovision). Light intensity and microscope settings were
optimized initially and then held constant. Care was taken to avoid
saturation at either end of the pixel intensity range (0–255). Mean
signal intensity in the CA3 stratum radiatum was divided by the back-
ground labeling in each section (calculated in the callosum of each
hemisphere). For each animal, an NPY staining score was obtained by
averaging the values obtained in individual sections. The NPY stain-
ing score was then correlated to the maximum behavioral seizure
score recorded for each mouse following KA treatment. Pearson cor-
relation analysis was performed using SigmaPlot 11.0.
Two-Bottle Preference Tests and Latent Inhibition
Two-bottle preference and latent inhibition test in a conditioned taste
aversion (CTA) paradigm were performed as previously described
(Bruno et al. 2007). For details, see Supplementary Materials and
Methods.
Conditioned Taste Aversion
SNAP-25+/+ (n = 10) and SNAP-25+/− (n = 12) mice were individually
housed during the CTA test. After mice were adapted to a restricted
drinking schedule (20 min/day for 4 days), they were exposed to a
saccharin solution (0.5%) followed 1 h later by a malaise-inducing in-
jection of LiCl (0.14 M, 2% body weight, i.p.). Beginning 48 h after
conditioning, mice could freely choose to drink either saccharin sol-
ution or tap water during 3 daily choice tests (ct1–ct3). The amount
of saccharin intake expressed as the percentage of total ﬂuid con-
sumed ([saccharin/saccharin + water] × 100) was taken as an aversion
index.
Object Recognition
Ten SNAP-25+/+ and 11 SNAP-25+/− mice were used. The novel object
recognition task was performed as described in Supplementary
Materials and Methods.
Sociability and Preference for Social Novelty Test
Ten SNAP-25+/+ and 12 SNAP-25+/− mice were used. The sociability
and preference for social novelty test was performed in a 3-chamber
transparent polycarbonate box as described in Supplementary
Materials and Methods.
Pharmacological Treatment
One week after basal EEG, animals were recorded 1 h before and for
2 h immediately after drug i.p. treatment: VLP sodium salt (250 mg/
kg), ethosuximide (ETO; 200 mg/kg), carbamazepine (CBZ; 50 mg/
kg), and nimodipine (NIMO; 10 mg/kg). VLP was given immediately
before HCl exposure in the CTA test, 20 min before T1 in the object
recognition test, and 20 min before sociability and social novelty test.
All drugs were dissolved in saline, NIMO in 10% ethanol, and saline
and CBZ in 1% Tween 80. The doses of ETO, VLP, and NIMO were
chosen for their ability to suppress differently induced seizures in
mice (Larkin et al. 1992; DeLorey et al. 1998; Liljelund et al. 2005;
Shitak et al. 2006; Marrosu et al. 2007; Chung et al. 2009). All the
drugs were given i.p. in a volume of 0.1 mL/10 g. Fresh drug solutions
were prepared daily. Drugs were purchased from Sigma-Aldrich
(St. Louis, MO).
Data Analysis
One-way ANOVA with repeated measures, 1-way factorial ANOVA
design with genotype (SNAP-25+/+, SNAP-25+/−) or 2-way ANOVA as
between subject factor were used. Post hoc analysis was done using
Tukey’s Bonferroni’s or Holm Sidak’s post hoc tests. Pairwise com-
parisons between genotypes or treatments were assessed with Stu-
dent’s t-test or Fisher exact probability tests. Correlation between the
maximum behavioral seizure score and NPY was performed using
SigmaPlot 11.0 and by Pearson correlation analysis. The signiﬁcance
threshold was set at P < 0.05. All statistical analyses were done with
software Prism, version 5 (GraphPad, San Diego, CA).
Results
Developmental Expression of SNAP-25 in Heterozygous
Mice Brain
Western blotting analysis of wild-type and heterozygous mice
cortices showed that SNAP-25 and syntaxin progressively in-
crease during brain development. To validate SNAP-25 levels
and to minimize development-related artifacts possibly
leading to erroneous data interpretation, both beta-III-Tubulin
and alpha-Tubulin were used as a loading marker for
SNAP-25 quantitation. Notably, SNAP-25 levels in heterozy-
gous mice tended to progressively increase relatively to
SNAP-25+/+ mice, indicating a partial compensation of protein
expression during postnatal development (*P < 0.05;
**P < 0.01; ***P < 0.001, t-test) (Fig. 1A,C). A comparable trend
was observed when SNAP-25 levels were normalized to alpha-
tubulin (*P < 0.05; **P < 0.01; ***P < 0.001, t-test) (Fig. 1D).
The protein increase was not accompanied by a parallel in-
crease in SNAP-25 mRNA levels, as assessed by qRT-PCR
analysis (Fig. 1B). No signiﬁcant difference in syntaxin
(Fig. 1E) or GAP-43 (Fig. 1F) expression was found between
SNAP-25+/+ and SNAP-25+/− mice during development. In the
adult SNAP-25+/− brain, a reduced level of SNAP-25 was de-
tected, in the absence of changes in SNAP-47, SNAP-29,
SNAP-23, the calcium-binding protein CB, and the vesicular
glutamate transporter vGlut1 (Fig. 1G).
Lack of Anatomical Alterations in SNAP-25+/− Brain
We analyzed whether anatomical alterations occur in brains of
SNAP-25+/− when compared with SNAP-25+/+ mice. The main
brain structures, cortex, hippocampus, and thalamus were
comparable in SNAP-25+/+ and SNAP-25+/− P2 mice, as indi-
cated by thionin staining (Fig. 2A,B). Normal cortical plate
and layers V and VI (Fig. 2D,F) and similar hippocampal CB
expression (Fig. 2C,E) were observed. Consistently, no major
differences in the main brain structures were detected
between SNAP-25+/+ and SNAP-25+/− adult animals (Fig. 2G,H).
The thickness of the cortices and the cortical lamination was
comparable, as indicated by thionin staining (Fig. 2I, J) and
immunostaining for SMI 311, which labels a subpopulation of
pyramidal cells mainly located in layers II–III and V (Fig. 2N,
O). The expression pattern of the calcium-binding proteins
CB and CR, identifying the subﬁelds of hippocampus (Fig. 2L,
M,R,S) and of CCK and NPY (Fig. 2P,Q,U,V) was identical in
SNAP-25+/+ and SNAP-25+/− mice. Also, DCX staining in the
subgranular zone, labeling migrating neuronal precursor cells
that eventually integrate into hippocampal circuitry (Parent
et al. 1997; van Praag et al. 2002), was comparable in amount
and distribution (Fig. 2W,X). Also, the distribution of excit-
atory and inhibitory terminals in CA1 hippocampal region
was not different between SNAP-25+/+ and SNAP-25+/− mice
(Fig. 2K,T). Finally, no major alterations were observed in the
barrel cortex of SNAP-25+/− mice when compared with wild
type, although further analysis may unveil slight segregation
differences (Fig. 2Y,Z). A quantitation of vGAT and vGlut1-
positive puncta, expressed as either a fraction of VAMP2-
positive puncta or a reciprocal ratio, revealed no signiﬁcant
differences between SNAP-25+/+ and SNAP-25+/− mice, at
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least in the CA1 region of the hippocampus (vGAT/VAMP2
ratio: SNAP-25+/+ 1 ± 0.080; SNAP-25+/− 0.972 ± 0.096;
P = 0.83; vGlut1/VAMP2 ratio: SNAP-25+/+ 1 ± 0.129;
SNAP-25+/− 0.975 ± 0.137; P = 0.89; vGAT/vGlut1 ratio:
SNAP-25+/+ 1 ± 0.085; SNAP-25+/− 1.024 ± 0.122; P = 0.88). Also,
no major difference was observed in vGlut2 distribution in the
dentate gyrus of SNAP-25+/+ and SNAP-25+/− mice (not shown).
SNAP-25+/− Mice, at the age of 7 Weeks, Show Motor
Hyperactivity due to Lack of Habituation
As a hyperactive phenotype has been described in coloboma
mice, which is reduced by the expression of the SNAP-25
transgene (Hess et al. 1996), we monitored spontaneous
motor activity in SNAP-25+/− mice at 7 weeks of age (Fig. 3)
and in the adult (Supplementary Table S1). The time course
of horizontal and vertical activity recorded every 10 min is
given in Figure 3A,B. During the ﬁrst 2-h recording, both gen-
otypes showed a similar horizontal and vertical activity.
However, during the following 2 h (120–240 min) SNAP-25+/−
mice failed to habituate, thus resulting more active than wild-
type littermates. S.c. injection of d-amphetamine (4 mg/kg)
increased horizontal activity in SNAP-25+/+ mice during the
ﬁrst hour after treatment (240–300 min), whereas in the fol-
lowing hour (300–360 min), the stimulant effect decreased
(Fig. 3A). Conversely, d-amphetamine appears not to exert
any effect on SNAP-25+/− mice in the ﬁrst hour after treat-
ment, whereas it signiﬁcantly reduced motor activity in the
following hour (Fig. 3A). However, it has to be noted that
removal of animals from the cage to perform injection,
induced an increase in motor activity. Indeed, a parallel group
of SNAP-25+/+ and SNAP-25+/− mice, subjected to the same
protocol, but treated with saline instead that amphetamine,
showed an increase in motor activity of 250% and 680%,
respectively. A recovery of motor function was obtained
during the last period. Vertical activity (Fig. 3B) was reduced
by treatment with d-amphetamine in both genotypes starting
from the ﬁrst hour and a partial recovery was reached at 360
min. The observed reduction of vertical movements was prob-
ably due to the intense horizontal activity. When the time
course was statistically evaluated in terms of 1-h each blocks,
signiﬁcant differences were obtained for horizontal (Fig. 3C)
and vertical activity (Fig. 3D) (see legend of Fig. 3C,D). A
normal locomotor activity was found in SNAP-25+/− adult
mice (Supplementary Table S1).
SNAP-25+/− Mice Display an Altered EEG Proﬁle and are
More Susceptible to Kainate-Induced Seizures
As SNAP-25 controls neurotransmitter release and VGCC
activity, we recorded the EEG proﬁle of SNAP-25+/− mice.
24-h cortical EEG recordings on freely moving animals
Figure 1. SNAP-25 levels in SNAP-25+/− cortices progressively increase during postnatal development. (A, C, and D) Western blotting analysis (A) and relative quantitation
(C and D) of SNAP-25+/+ and SNAP-25+/− cortices from E18, P7, P14, P30 and adult (3 months old) mice reveals a progressively higher expression ratio in SNAP-25+/− mice
during postnatal development (normalized SNAP-25 levels: (C) E18, SNAP-25+/+ (n= 6) 1 ± 0.056, SNAP-25+/− (n= 7) 0.38 ± 0.089; P7, SNAP-25+/+ (n= 9) 1 ± 0.091,
SNAP-25+/− (n=5) 0.63 ± 0.049; P14-30, SNAP-25+/+ (n=8) 1 ± 0.054, SNAP-25+/− (n= 8) 0.71 ± 0.092; adult, SNAP-25+/+ (n= 6) 1 ± 0.068, SNAP-25+/− (n= 7)
0.75 ± 0.042. *P< 0.05; **P< 0.01; ***P<0.001, unpaired Student’s t-test. (D) E18, SNAP-25+/+ (n= 5) 1 ± 0.025, SNAP-25+/− (n= 6) 0.511± 0.061, P< 0.0001;
P7, SNAP-25+/+ (n= 5) 1 ± 0.095, SNAP-25+/− (n= 5) 0.763± 0.0312, P<0.05; P14-30, SNAP-25+/+ (n=9) 1 ± 0.077, SNAP-25+/− (n= 8) 0.777± 0.065, P< 0.05;
adult, SNAP-25+/+ (n=3) 1 ± 0.012, SNAP-25+/− (n= 3) 0.85 ± 0.022, P< 0.01. (B) RT-qPCR analysis reveals that SNAP-25 mRNA is about half in SNAP-25+/− mice at all
developmental stages (normalized fold expression: P7, SNAP-25+/+ (n= 2) 1 ± 0.044, SNAP-25+/− (n= 2) 0.551± 0.094; P14-30, SNAP-25+/+ (n= 4) 1 ± 0.089,
SNAP-25+/− (n= 5) 0.441± 0.056; adult, SNAP-25+/+ (n= 3) 1 ± 0.034, SNAP-25+/− (n= 3) 0.470 ± 0.046. *P<0.05; ***P< 0.001, unpaired Student’s t-test). (E)
Quantitation of syntaxin expression at different developmental stages shows no differences in the protein expression between SNAP-25+/+ and SNAP-25+/− animals (E18,
SNAP-25+/+ (n=2) 1 ± 0.160, SNAP-25+/− (n=2) 0.997 ± 0.095; P7, SNAP-25+/+ (n=3) 1 ± 0.023, SNAP-25+/− (n=3) 0.978± 0.051; P14-30, SNAP-25+/+ (n= 6)
1 ± 0.087, SNAP-25+/− (n= 6) 1.081± 0.115;adult, SNAP-25+/+ (n= 2) 1 ± 0.227, SNAP-25+/− (n= 2) 0.909 ± 0.090) (F) Western blotting analysis of GAP43 expression
in mice cortices at early developmental stages (E18, P7) reveals the absence of differences between SNAP-25+/+ and SNAP-25+/− mice (E18, SNAP-25+/+ (n= 5)
1 ± 0.099, SNAP-25+/− (n= 5) 1.183 ± 0.169; P7, SNAP-25+/+ (n= 4) 1 ± 0.085, SNAP-25+/− (n=4) 1.093± 0.102). (G) Western blotting analysis of SNAP-25+/+ and
SNAP-25+/− adult cortices shows absence of major alterations in the expression of different brain markers.
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revealed that heterozygous mice displayed frequent spikes of
high amplitude (Fig. 4A–C), which, however, did not lead to
spontaneous seizures. In only one case (a het mouse display-
ing 365 spikes/24 h), we could observe occurrence of general-
ized seizures following handling. Abnormal EEG pattern was
observed in all tested SNAP-25+/− mice. The percentage of
SNAP-25+/− mice showing abnormal discharges was signiﬁ-
cantly larger than of SNAP-25+/+ mice (Fig. 4C). Epileptiform
discharges were also detected by EEG electrodes positioned
at hippocampal level (not shown). Furthermore, SNAP-25+/−
mice were more susceptible to seizures induced by kainate
(KA). Figure 4D shows the time-course of the behavioral
response of SNAP-25+/+ and SNAP-25+/− mice to 35 mg/kg
KA over a 3-h period after i.p. administration. In all mice, this
dose of KA resulted within the ﬁrst 10 min in immobility and
staring, followed by head bobbing and isolated limbic motor
(Stage 4) seizures, characterized by forelimb clonus and
rearing. Overall, latency to the ﬁrst Stage 4 seizure did not
differ between SNAP-25+/+ (18.5 ± 5.5 min) and SNAP-25+/−
mice (18.2 ± 3.6 min; P > 0.05, unpaired t-test). However,
while SNAP-25+/+ animals only displayed isolated limbic
motor seizures, SNAP-25+/− mice rapidly progressed to Stage
Figure 2. Cytoarchitectural analysis of SNAP-25+/+ and SNAP-25+/− mice brain. (A–F) Analysis of P2 brain. Photomicrographs of Thionin-stained coronal sections of brain from
SNAP-25+/+ (A) and SNAP-25+/− (B) mice show no difference in size and cytoarchitecture of the main brain structures. High magniﬁcation of developing cortices reveal
comparable cortical lamination (D and F). CB expression in hippocampus shows the same pattern of distribution (C and E). (G–Z) Analysis of adult brain. Photomicrographs of
Thionin-stained coronal sections of brain reveal comparable main brain structures, cortex, hippocampus and thalamus, in SNAP-25+/+ (G) and SNAP-25+/− (H) mice. The
thickness and layering of the cortices are not altered in SNAP-25+/− mice (I and J) as conﬁrmed by immunostaining for the anti-nonphosphorylated neuroﬁlaments SMI311 (N
and O). Similar pattern of CB immunoreactivity is evident in SNAP-25+/+ (L) and SNAP-25+/− (M): note CA1 and CA2 pyramidal layers, mossy ﬁbers and dentate gyrus intensely
stained. The labeling for CCK (P and Q) and CR (R and S), mainly localized in the molecular layer of dentate gyrus, is identical in SNAP-25+/+ and SNAP-25+/− mice. High
magniﬁcation images of dentate gyrus, show NPY (U and V) and DCX (Y and X) immunoreactivity in the polymorphic layer and in the subgranular zone respectively. No gross
difference in synaptic excitatory (vGlut1, red) and inhibitory (vGAT, green) pattern is detectable in CA1 hippocampal regions (K and T). vGlut2 staining of the barrel cortex in
SNAP-25+/+ and SNAP-25+/− mice (Y and Z). Scale bar = 3 mm for A and B; 300 µm for C,E; 400 µm for D,F; 2,4 mm for G,H; 330 µm for I,J,N,O; 20 µm for K,T; 450 µm for
L,M; 510 µm for P,Q; 490 µm for R,S; 230 µm for U-X; 250 µm for Y,Z.
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5 (status epilepticus) and showed continuous generalized
activity lasting for about 2 h. The average time of Stage 5
seizure onset in SNAP-25+/− mice was 45.7 ± 6.5 min. Mor-
tality rate following KA administration was comparable
between SNAP-25+/+ and SNAP-25+/− mice (SNAP-25+/+, 4/10;
SNAP-25+/−, 3/10). SNAP-25+/− mice had signiﬁcantly higher
behavioral scores than SNAP-25+/+ mice starting from 40 min
after KA (Fig. 4D). Thus, the progression of clinical signs fol-
lowing KA treatment was dramatically different in SNAP-25+/+
and mutant animals. Saline-injected animals of both geno-
types showed no behavioral seizures during the whole period
of observation (not shown). NPY immunostaining revealed
extensive loss of interneurons in SNAP-25+/− when compared
with controls (Fig. 4E), indicating that the higher seizure
scores of SNAP-25+/− mice are paralleled by loss of hilar
neurons. Moreover, there was a robust upregulation of NPY
immunoreactivity in the mossy ﬁber pathway of all SNAP-25+/−
mice treated with KA (Fig. 4E). Indeed, the quantitative analysis
indicated that NPY labeling in the CA3 stratum radiatum of
KA-treated het mice was signiﬁcantly upregulated with
respect to KA-treated wt animals (t-test, P = 0.009; Fig. 4F).
Examination of individual animals revealed a signiﬁcant cor-
relation between NPY intensity values and the maximum be-
havioral seizure score recorded after KA (Pearson correlation
coefﬁcient = 0.69, P = 0.025; Fig. 4G). In keeping with the well-
known resistance of C57Bl/6 mouse strains to KA-induced
pyramidal damage (Schauwecker and Steward 1997), CA1/
CA3 cell loss was not found in Nissl-stained sections from KA-
treated SNAP-25+/+ and SNAP-25+/−mice (not shown).
SNAP-25+/− are Impaired in Nonspatial Associative
Learning Tasks
Before performing memory tasks SNAP-25 mice were
initially checked for their general health, reﬂex, sensory abil-
ities and emotional-like response (for methodological details
see Supplementary Materials and Methods). As reported in
Supplementary Table S1 and Supplementary Results,
Figure 3. SNAP-25+/− mice display hyperactivity at 7 weeks of age. (A and B) Time-course of locomotor activity evaluated before (4 h of baseline) and after (3 h) amphetamine
injection. After 2 h habituation, SNAP-25+/− mice exhibited an increased horizontal (A) and vertical (B) activity in comparison to SNAP-25+/+ mice. Photocell beam interruptions
were recorded every 10 min. During both the ﬁrst and second hour, the number of counts, recorded every 10 min, were pooled and shown as mean ± standard error of means
(SEM). (C and D) The time-course obtained in A and B was also evaluated as mean (±SEM) of horizontal and vertical activity counts in blocks of 1-h each period. Acute
d-amphetamine treatment (4 mg/kg), given s.c. at 240 min (arrow), reduces the number of movements only in SNAP-25+/− mice at the 2 h and a complete recovery was
observed at the 3 h. (C) Mean horizontal counts are higher in SNAP-25+/− mice before amphetamine administration (pre) (average of the number of counts during the 120–240
min period), whereas no signiﬁcant change is observed after amphetamine injection. Conversely, in SNAP-25+/+ mice, amphetamine increases horizontal activity during the ﬁrst
hour and returns to baseline within the 3 h. Genotype as between subject factor and treatment as within factor, genotype: F1,56 = 113, P<0.0001; time : F3,56 = 61.57,
P<0.0001; genotype X time F3,56 = 52.47, P<0.0001, 2-way repeated measure of variance, Bonferroni’s post hoc analysis. SNAP-25
+/+ mice vs SNAP-25+/− mice, Pre:
**P<0.01; SNAP-25+/+ mice ﬁrst hour vs pre: $$ P<0.01; SNAP-25+/− mice 1 h and 3 h vs 2 h vs: ##P<0.001, ###P< 0.0001. (D) The mean vertical activity counts
evaluated over 1 h-period (mean ± SEM) are higher in SNAP-25+/− mice before amphetamine (pre), whereas a signiﬁcant reduction occurs after amphetamine injection during
the ﬁrst and second hour. In SNAP-25+/+ mice amphetamine decreases horizontal activity during the ﬁrst hour only. Partial recovery was obtained at the 3 h in SNAP-25+/−
while a complete recovery was found at the 3 h in Snap-25+/+ mice. Genotype as between subject factor and treatment as within factor, genotype: F1,56 = 32.06, P< 0.0001;
time : F3,56 = 30.83, P< 0.0001; genotype X time F3,56 = 12.79, P< 0.0001, 2-way repeated measure of variance, Bonferroni’s post hoc analysis. SNAP-25
+/+ mice vs
SNAP-25+/− mice, Pre: ***P< 0.001; SNAP-25+/+ or SNAP-25+/− mice vs corresponding Pre: $P< 0.01,$$$ P< 0.01, $$$ P< 0.01. n= 8 per group.
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Figure 4. SNAP-25+/− mice display abnormal EEG proﬁle and are more susceptible to kainate-induced convulsions. (A) 24-h representative EEG trace from a SNAP-25+/+ (left)
and a SNAP-25+/− (right) mouse. The SNAP-25+/− mouse shows increased spike frequency, as indicated by the quantitative evaluation in the bottom portion of the trace. For
each EEG recording, the histogram of the maximum positive increments over overlapping 20 ms windows was derived. Increments above a threshold determined according to
the increments distribution through an unsupervised approach (Manfredi et al. 2009) and whose amplitude was greater than twice the background were considered as spikes.
(B) Magniﬁcation of representative EEG traces (30-s) from one SNAP-25+/+ and one SNAP-25+/− mouse. (C) The average spike number (±SEM) recorded for 24 h is
signiﬁcantly higher in SNAP-25+/− versus SNAP-25+/+ (**P<0.01, t-test) (top) and the percentage of SNAP-25+/− mice showing abnormal discharges is greater (**P<0.01,
Fisher exact probability test) (bottom). (D) Increased susceptibility to KA-induced seizures in SNAP-25+/− mice. Progression of behavioral changes after systemic KA
administration (35 mg/kg, i.p.) in SNAP-25+/+ and SNAP-25+/− mice over a 3- h observation period. Genotype as between-subject factor and time within subject factor,
genotype: F1,18 = 6.39, P=0.02; effect of time: F1,13 = 10.85 P< 0.001; genotype x time interaction: F1,30 = 0.71, P= 0.70, 2-way repeated measure analysis of variance,
P< 0.05, Holm Sidak post hoc test. Data represent mean seizure scores ± SEM. SNAP-25+/+ mice versus SNAP-25+/− mice: *P< 0.05. (E) Upregulation of NPY following
seizures in SNAP-25+/− mice. Coronal sections from the dorsal hippocampus of KA-treated animals (left, SNAP-25+/+ mouse; right, SNAP-25+/− mouse). NPY staining in the
dentate gyrus (top panels) and CA3 region (bottom panels): note loss of interneurons and strong upregulation of NPY in the mossy ﬁber pathway in SNAP-25+/− mice. Scale
bar = 150 μm. (F) Quantiﬁcation of NPY staining intensity in KA-treated mice. The histograms report average ± SEM of the NPY signal-to-background ratio (intensity of NPY label
in CA3 stratum radiatum divided by the background staining) in SNAP-25+/+ (open bars) and SNAP-25+/− animals (ﬁlled bars). There is a signiﬁcant upregulation of NPY labeling
in KA-treated het mice. **, P<0.01, Student’s t-test. (G) Scatter plot showing NPY staining values and maximum KA-induced seizure score for each individual mouse (wt, open
circles; het, ﬁlled circles). There is a signiﬁcant correlation between the 2 variables (Pearson correlation coefﬁcient = 0.69, P=0.025).
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SNAP-25+/− mice displayed normal gross behavior and
emotional-like reactivity (Supplementary Results and
Fig. S1). SNAP-25+/− mice were not impaired in spatial learn-
ing and memory (Supplementary Materials and Methods,
Results, and Fig. S2).
SNAP-25+/− and SNAP-25+/+ mice were then tested for
implicit associative learning (Fig. 5). There was a signiﬁcant
difference among different taste solutions intake in the
2-bottle preference test (Fig. 5A, top panel) in SNAP-25+/−
mice. A strong preference for water over quinine and for sac-
charin over plain water, suggesting a normal taste sensitivity,
was found. There was no signiﬁcant difference in HCl (0.008
M) intake between SNAP-25+/+ and SNAP-25+/− mice. When
mice were tested for the latent inhibition of CTA (Fig. 5A,
middle panel), LiCl injection did not induce any CTA in
SNAP-25+/− mice (41% less HCl consumed by non-pre-
exposed SNAP-25+/+ mice during the test trial than during the
conditioning trial vs. 91% consumed by SNAP-25+/− mice).
Pre-exposed mice of both genotypes consumed nearly as
much HCl (98%, SNAP-25+/+ mice, and 112%, SNAP-25+/−
mice) during the test trial, as they did during the conditioning
trial, excluding an impairment in viscerally related associative
learning and memory (Fig. 5A, middle panel). CTA impair-
ment was not due to the poor discrimination between HCl
and plain water. Indeed, when tested for CTA with saccharin,
SNAP-25+/− mice exhibited a signiﬁcantly attenuated CTA,
as they avoided the saccharin solution to a lesser degree
compared with SNAP-25+/+ controls during choice tests
(Fig. 5A, bottom panel). Mutant and control mice drank com-
parable amounts of ﬂuid during the conditioning sessions
(not shown), excluding a general alteration of ﬂuid consump-
tion or taste.
When tested for the novel object recognition (Fig. 5B and
Supplementary Fig. S3), no signiﬁcant difference was detected
in the amount of time the mice spent exploring the 2 objects
during the familiarization (T1) phase (data not shown), indi-
cating that both genotypes had the same motivation to
explore the object. However, SNAP-25+/− mice spent signiﬁ-
cantly less time exploring the novel object compared with the
familiar one, as shown by a signiﬁcant decrease of the dis-
crimination index. This was not due to altered sensorial par-
ameters as all mice appeared in health, displaying normal
motor coordination, sensory abilities and were not aggressive
(Supplementary Table S1).
When tested for sociability, SNAP-25+/+ mice behaved nor-
mally, spending longer time to explore the compartment with
the stranger mouse than the empty cage. Conversely,
SNAP-25+/− mice spent the same amount of time in the 2
compartments (Fig. 5C, top panel). Moreover, when subjected
to a social recognition test, SNAP-25+/− mice remained close
to the new or old stranger for the same time, suggesting
altered social recognition (Fig. 5C, bottom panel). Both geno-
types spent equal time in the central compartment.
Antiepileptic Drugs Normalize the EEG Proﬁle and
Improve the Cognitive Defects in SNAP-25+/− Mice
We next investigated whether treatment with antiepileptic
drugs was able to normalize the altered EEG proﬁle of
SNAP-25+/− mice. Treatment with different antiepileptic drugs
signiﬁcantly reduced epileptiform activity (Fig. 6A). The most
potent effect was observed after treatment with VLP (95%
reduction) and ETO (80% reduction), whereas a partial but
signiﬁcant reduction was obtained with CBZ (60% reduction)
or with the calcium antagonist NIMO (35% reduction)
(Fig. 6A). The mean number of spikes was signiﬁcantly
reduced in SNAP-25+/− mice treated with VLP (Fig. 6B,C).
Notably, VLP, given 2 h before test performance, signiﬁcantly
reversed the cognitive deﬁcit of SNAP-25+/− mice in the object
recognition task (Fig. 6D). Treatment with VLP per se slightly,
but not signiﬁcantly, worsened cognitive abilities in
SNAP-25+/+ mice (not shown), in agreement with previous
reports indicating impaired nonspatial hippocampal memory
in mice (Sgobio et al. 2010) and reduced mental speed in
humans (Mula and Trimble 2009) treated with VLP. Treatment
with VLP also reversed the CTA impairment (Fig. 6E) and nor-
malized the defects in social memory (Fig. 6G), being
however ineffective in restoring sociability (Fig. 6F). Treat-
ment with VLP slightly reduced the cognitive performance in
SNAP-25+/+ mice (data not shown).
Discussion
Human genetic data link SNAP-25 to a range of psychiatric
and neurologic conditions. In particular, reductions of protein
expression at levels comparable to those occurring in the
SNAP-25+/− mice have been described in psychiatric patients,
with 49% less SNAP-25 immunoreactivity detected, for
example, in the hippocampus of patients with schizophrenia
compared with the control group (Thompson et al. 2003).
SNAP-25+/− mice provide therefore a useful model to better
understand the role of the gene and test potential new thera-
pies. As a relevant added value, the study was carried out in 3
distinct European laboratories, thus reducing the possibility
that interactions of genotype with the speciﬁc laboratory con-
ditions may impact behavioral results.
Like coloboma mice (Hess et al. 1996) and homozygous
mutant mice in which Ser187 of SNAP-25 is substituted with
Ala (Kataoka et al. 2011), SNAP-25+/− mice display hyperac-
tivity, although this alteration occurs at 7 postnatal weeks and
is normalized in the adult age. However, SNAP-25+/− mice are
not anxious and, differently from coloboma, they do not
display motor coordination impairment and PPI deﬁcit (Gunn
et al. 2011). This could result from the severe sensory deﬁcits
of coloboma mice, which are blind and deaf, while SNAP-25+/−
mice display no sensory abnormalities. Also, Coloboma mice
show a disrupted latent inhibition, a measure of selective at-
tention, without CTA deﬁcits. SNAP-25+/− mice, conversely,
exhibit defects in implicit associative learning. All together,
these data suggest that the behavioral proﬁle of coloboma
mice may be inﬂuenced by the other genes deleted besides
SNAP-25 (Gunn et al. 2011).
A major accomplishment of our study is the ﬁnding that
SNAP-25 levels reduction is associated with diffuse network
hyperexcitability, which does not lead to spontaneous convul-
sive behavior. Our data are in line with the signiﬁcantly
higher incidence of epilepsy in pathologies characterized by
SNAP-25 alterations. In particular, the incidence of epilepsy is
about 6 times higher in patients with schizophrenia than in
controls (Chang et al. 2011) and ADHD children are 2.7 times
more likely to have epilepsy (Davis et al. 2010), also showing
higher occurrence of subclinical epileptiform activity (Richer
et al. 2002; Becker et al. 2004). Although the mechanisms by
which reduced levels of SNAP-25 lead to network
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Figure 5. SNAP-25+/− mice are impaired in implicit associative learning tasks. (A) Two-bottle test (top). SNAP-25+/− mice consume less quinine than water (***P< 0.0001)
and more saccharin than plain water (**P= 0.0003) (t-test). There is no signiﬁcant difference in HCl (0.008 M) intake between SNAP-25+/+ and SNAP-25+/− mice (P= 0.23).
Latent inhibition of CTA response (middle panel). SNAP-25+/+ non-pre-exposed mice show a signiﬁcant decrease of HCl intake in comparison with pre-exposed animals,
indicating a latent inhibition. No signiﬁcant difference in HCl consumption between non-pre-exposed and pre-exposed SNAP-25+/− mice occurs, indicating the lack of CTA.
Genotype as between subject factor and treatment as within factor, genotype: F1,36 = 3.52, P=0.07; treatment : F1,36 = 13.11, P=0.001; genotype X treatment
F1,36 = 3.87, P=0.05, 2-way repeated measure of variance, Bonferroni’s post hoc analysis. SNAP-25
+/+ or SNAP-25+/− mice versus SNAP-25+/+ non-pre-exposed:
**P< 0.01, ***P<0.001, Bonferroni’s post hoc analysis. CTA test (bottom panel). SNAP-25+/− mice drink signiﬁcantly more saccharin - as expressed in percentage of total
ﬂuid intake - than SNAP-25+/+ mice during the 3-daily choice tests following aversive conditioning (F1,40 = 6.32, P= 0.02, one-way repeated measure of variance, Tukey’s post
hoc test). *P<0.05. (B) Object recognition test. Mice were allowed to explore an identical pair of objects and after 120 min they are presented with a familiar and a new
object. SNAP-25+/− mice show no net preference between novel and familiar objects, as shown by the reduced discrimination index (**P<0.0001, unpaired t-test). (C)
Sociability and social novelty test. SNAP-25+/− mice show impaired social interaction (top), as they spend the same amount of time exploring a stranger mouse or an empty
cage in a social choice paradigm. Genotype as between subject factor and compartment as within factor, genotype: F1,36 = 0.77, P= 0.38; compartment: F1,36 = 27.88,
P< 0.0001; genotype X compartment F1,36 = 4.68, P= 0.03, 2-way repeated measure of variance, Bonferroni’s post hoc analysis. SNAP-25
+/+, stranger versus SNAP-25+/+
mice, empty cage and center: ***P<0.01, SNAP-25+/− mice versus center $$P< 0.01, $$$P< 0.001. Social novelty (bottom). SNAP-25+/− mice fail to show any preference
for a novel mouse in a social recognition task. In contrast, SNAP-25+/+ mice spend more time exploring the new stranger versus old stranger and center. Genotype as between
subject factor and compartment as within factor, genotype: F1,36 = 0.3, P= 0.8; compartment: F1,36 = 22.44, P<0.0001; genotype X compartment F1,36 = 19.09,
P= 0.0001, 2-way repeated measure of variance, Bonferroni’s post hoc analysis. SNAP-25+/+ mice: new stranger versus old stranger and center, ***P< 0.001. SNAP-25+/−
old or new stranger versus center: $$$P< 0.001. Error bars in all ﬁgures refer to mean ± SEM of 8-16 for each group.
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Figure 6. Antiepileptic drugs reverse EEG alterations and learning defects in SNAP-25+/− mice. (A) Treatment with VLP (250 mg/kg), ethosuximide (ETO) (200 mg/kg),
carbamazepine (CBZ) (50 mg/kg), and nimodipine (NIMO) (10 mg/kg) to SNAP-25+/− mice signiﬁcantly reduces spike activity (genotype as between subject factor and
treatment as within factor, genotype: F4,45 = 20.85, P= 0.0001, one-way repeated measure of variance, Tukey’s post hoc test) (**P< 0.001, ***P< 0.001 compared with
vehicle; $$P< 0.01 compared with NIMO). (B) EEG recording of one representative SNAP-25+/− mouse treated with VLP showing a decreased spike activity in comparison to
one SNAP-25+/+ mouse. (C) The mean number of spikes recorded for 60 min in SNAP-25+/− mice is signiﬁcantly reduced by VLP compared with vehicle. (F1,36 = 5.44,
P=0.2; treatment: F1,36 = 19.65, P< 0.0001; genotype X treatment: F1,36 = 12.50, P= 0.001, Bonferroni’s post hoc analysis). SNAP-25
+/+ versus SNAP-25+/− mice:
*P< 0.05; VLP-treated SNAP-25+/− mice versus vehicle-treated SNAP-25+/− mice: $$$ P< 0.0001. (D) VLP reverses the defect in object recognition test. The reduced
discrimination index, found in SNAP-25+/− mice, is reversed by pretreatment with VLP given i.p. at the dose of 250 mg/kg, 20 min before T1 trial (genotype as between subject
Cerebral Cortex February 2014, V 24 N 2 373
hyperexcitability are not deﬁned, a defective modulation of
VGCCs by reduced SNAP-25 levels may be implicated (Atlas
2001; Zamponi 2003; Catterall and Few 2008; Pozzi et al.
2008; Condliffe et al. 2010). Indeed, analysis of calcium
current amplitude in thalamocortical neurons of coloboma
mice revealed an increase in the peak current density of low
voltage-
activated currents that precedes the onset of spike-wave dis-
charges (Zhang et al. 2010). Notably, acute downregulation of
SNAP-25 in glutamatergic neurons by siRNA reduces calcium
currents, and consistently, SNAP-25+/− glutamatergic but not
GABAergic neurons display larger calcium current density
(Condliffe et al. 2010). In line with these results, electro-
physiological analysis of cultured neurons has demonstrated
that SNAP-25+/− glutamatergic neurons shift from paired
pulse facilitation to paired pulse depression, thus indicating
an increase in presynaptic release probability (F. Antonucci,
R. Morini and M. Matteoli, unpublished observations).
Although a direct correlation between electrophysiological
properties of cultured neurons and mice behavior cannot be
easily drawn, these data suggest that an excitatory–inhibitory
imbalance could be at the basis of the SNAP-25+/− phenotype.
Addressing this possibility will require an in depth analysis of
excitatory and inhibitory neurotransmission in different areas
of the SNAP-25+/− brain. Indeed, quite surprisingly, cognitive
deﬁcits in SNAP-25+/− mice occur predominantly in implicit
associative learning tasks, whereas no defects were found in
explicit spatial orientation tasks. This may be related to the
heterogeneous SNAP-25 levels in distinct neuronal hippocam-
pal subpopulations. Indeed, 3-4-fold higher protein levels
occur in CA3 region compared with CA1 (Oyler et al. 1989;
Geddes et al. 1990), with CA3 possibly serving as predomi-
nant associative memory network, and CA1 being critical for
long-term spatial memory (Nakazawa et al. 2003). Notably,
ADHD children display impaired associative implicit learning,
mediated by frontal-striatal-cerebellar circuits, but normal
spatial contextual learning depending upon the medial tem-
poral lobes (Barnes et al. 2010). Under this respect, an analy-
sis, in SNAP-25+/− mice, of the synapses where SNAP-25
expression is in fact lower at early developmental stages could
be useful for identifying the substrate of impaired forward sig-
naling even if compensated by later network maturation.
The abnormal EEG activity of SNAP-25+/− mice could be a
factor contributing to the learning deﬁcits. Indeed, it has
been proposed that the cognitive effects of epileptiform dis-
charges may be very similar to the cognitive impact of short
epileptic seizures (Aarts et al. 1984). Furthermore, a decline
in IQ scores, similar to that seen in patients with nonconvul-
sive epileptic seizures, was reported in patients with fre-
quent episodes of epileptiform discharges (Brinciotti et al.
1989; Aldenkamp et al. 2005, 2010). Interestingly, treatment
with antiepileptic drugs, or with the calcium antagonist
NIMO, largely normalize the altered EEG proﬁle of
SNAP-25+/− mice, the larger beneﬁcial effects produced by
VLP and ETO, that is, drugs effective at controlling absence
seizures. It is possible that a common mechanism of action is
shared by these antiepileptic drugs. At clinically relevant con-
centrations, ETO inhibits calcium T currents in thalamic
neurons (Coulter 1997); CBZ has been proposed to modulate
L- and P-type VGCC (Yoshida et al. 2007), whereas VLP
blocks the voltage-gated sodium channels and T-type calcium
channels (Rosenberg 2007). Finally, the calcium channel
blocker NIMO (Mikati et al. 2004), acting as aspeciﬁc antag-
onist on L-, N-, P/Q-, R-, and T-type VGCC, has been indi-
cated by preclinical and clinical studies potentially useful in
the treatment of various disorders of the central nervous
system (Choudhary et al. 2006). Along this line, it is notable
that CBZ has been reported to exert a positive effect on a
child with ADHD and subclinical EEG discharges without sei-
zures (Laporte et al. 2002), whereas treatment with VLP ap-
peared to ameliorate ADHD symptoms in fragile X syndrome
boys (Torrioli et al. 2008). Our data offer a logical frame for
explaining these ﬁndings, by directly linking reduction of
SNAP-25, generation of subclinical epileptiform discharges
and learning impairments. They also suggest that human
genetic variations, resulting in the reduction of protein
expression, may create a hyperexcitable physiopathological
background susceptible to functional failures and demonstrate
the beneﬁcial effect of antiepileptic drugs in ameliorating the
abnormal excitability and cognitive impairments linked to
reduction of SNAP-25 levels.
Supplementary Material
Supplementary material can be found at: http://www.cercor.
oxfordjournals.org/
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factor and treatment as within factor, genotype: F1,36 = 23.37, P<0.0001; treatment: F1,36 = 14.76, P= 0.0005; genotype X treatment: F1,36 = 25.42, P< 0.0001, 2-way
repeated measure of variance Bonferroni’s post hoc analysis). SNAP-25+/+ mice, vehicle versus SNAP-25+/− mice, vehicle: $P< 0.05; Valproate-treated SNAP-25+/− mice
versus saline-treated SNAP-25+/− mice: **P<0.001. (E) VLP reverses CTA impairment. SNAP-25+/− mice are unable to associate sucrose intake with a malaise induced by LiCl
given subcutaneously (63 mg/kg) in the conditioning day. Pretreatment with VLP, given immediately before HCl exposure, fully reverses the lack of CTA (genotype as between
subject factor and treatment as within factor, genotype: F1,36 = 4.34, P= 0.04; treatment: F1,36 = 4.45, P=0.04; genotype X treatment: F1,36 = 3, P= 0.05, 2-way repeated
measure of variance. Bonferroni’s post hoc analysis). SNAP-25+/+ versus SNAP-25+/− mice: $$ P<0.01; Valproate-treated SNAP-25+/− mice versus vehicle-treated
SNAP-25+/− mice: **P< 0.001. (F) Effect of VLP in sociability in SNAP-25+/− mice. VLP do not reverse the impaired social interaction (genotype as between subject factor
and treatment as within factor, genotype: F1,36 = 55.48, P< 0.0001; treatment: F1,36 = 1.45, P=0.22; genotype X treatment: F1,36 = 1.45, P=0.2, 2-way repeated measure
of variance, Bonferroni’s post hoc analysis). SNAP-25+/+ versus SNAP-25+/−: $$P< 0.01. (G) VLP is effective in improving putative social memory (genotype as between
subject factor and treatment as within factor, genotype: F1,36 = 23.37, P< 0.0001; treatment: F1,36 = 14.76, P= 0.0005; genotype X treatment: F1,36 = 25.42, P<0.0001,
2-way repeated measure of variance, Bonferroni’s post hoc analysis). SNAP-25+/+ vehicle mice versus SNAP-25+/− vehicle mice: $$P< 0.01). SNAP-25+/− VLP-treated versus
SNAP-25+/− vehicle-treated mice: ***P< 0.001. Bars represent the mean ± SEM of 8–12 animals for each group.
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